

Detailed and Complete Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. – 23. (Canceled)

24. (Previously presented) A method for preparing a factor VIII solution comprising:

(a) obtaining a starting factor VIII solution comprising factor VIII-von Willebrand factor (factor VIII-vWF) complexes; and

(b) filtering said solution through a hydrophilic virus filter, wherein the virus filter has a mean pore size of 13 to 17 nm and wherein the filtering occurs in the presence of CaCl_2 ions, at a pressure of less than 0.3 bar and a temperature of about $35 \pm 5^\circ\text{C}$; and wherein the filtered solution is free of viruses and devoid of high molecular forms of vWF and factor VIII-vWF complexes.

25. (Previously presented) The method according to claim 24, further comprising dissociating factor VIII-vWF complexes of the starting solution prior to (b) filtering.

26 – 28. (Canceled)

29. (Previously presented) The method according to claim 24, wherein the CaCl_2 is present in the solution from 0.2 M to saturation.

30. (Canceled)

31. (Previously presented) The method according to claim 24, wherein the CaCl_2 is present in the solution from 0.35 M to saturation.

32. (Canceled)

33. (Previously presented) The method according to claim 31, wherein the filter has a pore size of 15 nanometers.

34. (Previously presented) The method according to claim 31, wherein the filter is used at a pressure lower than 0.2 bar.

35. (Canceled)

36. (Previously presented) The method according to claim 25, wherein the factor VIII-vWF complexes of the starting factor VIII solution are dissociated by ion exchange chromatography.

37. (Previously presented) The method according to claim 36, wherein the starting factor VIII solution of (a) is derived from a cryoprecipitated fraction of plasma.

38. (Canceled)

39. (Canceled)

40. (Previously presented) The method according to claim 24, wherein the starting factor VIII solution of (a) is derived from a cryoprecipitated fraction of plasma.

41. (Previously presented) The method according to claim 24, wherein the starting factor VIII solution is treated with an effective amount of an anti-viral solvent, a detergent, or both.

42. (Previously presented) The method according to claim 24, wherein the starting factor VIII solution is immunopurified.

43. (Previously presented) The method according to claim 24, wherein the starting factor VIII solution comprises recombinantly produced factor VIII.

44 – 51. (Canceled)

52. (Previously presented) The method according to claim 40, wherein the starting factor VIII solution is obtained by a further heparin precipitation.